{"transactions":[{"id":952505,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock, par value $0.001","published_at":"2026-01-05T16:30:26.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":27322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service.  The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 76,705 shares underlying deferred restricted stock units."}],"balance_after":192397,"source":{"system":"sec-edgar","filing":"0001172659-26-000002","document":"form4-01052026_040120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000117265926000002/form4-01052026_040120.xml","form_type":"4"}},{"id":1315723,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock, par value $0.001","published_at":"2025-01-03T16:28:30.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":49383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service.  The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 49,383 shares underlying deferred restricted stock units."}],"balance_after":165075,"source":{"system":"sec-edgar","filing":"0001415889-25-000444","document":"form4-01032025_090127.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000141588925000444/form4-01032025_090127.xml","form_type":"4"}},{"id":1693506,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-01-03T16:52:27.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service."}],"balance_after":115692,"source":{"system":"sec-edgar","filing":"0001104659-24-000912","document":"tm241755-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000110465924000912/tm241755-7_4seq1.xml","form_type":"4"}},{"id":1792131,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-31T14:45:51.000Z","date":"2023-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":5.21,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-23-047825","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000120919123047825/doc4.xml","form_type":"4"}},{"id":1792130,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-31T14:45:51.000Z","date":"2023-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.8,"expiration_date":"2031-12-22","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-047825","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000120919123047825/doc4.xml","form_type":"4"}},{"id":1792129,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-31T14:45:51.000Z","date":"2023-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":1.87,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-23-047825","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000120919123047825/doc4.xml","form_type":"4"}},{"id":1792128,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-31T14:45:51.000Z","date":"2023-08-31","kind":"other","planned":false,"acquired":false,"shares":1163861,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares beneficially owned by JJL Pardes, LLC, of which the Reporting Person is the sole managing member."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-047825","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000120919123047825/doc4.xml","form_type":"4"}},{"id":1792127,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-31T14:45:51.000Z","date":"2023-08-31","kind":"other","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-047825","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000120919123047825/doc4.xml","form_type":"4"}},{"id":1870425,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T16:07:23.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continued service to the Issuer on each applicable vesting date, the option vests as to 1/12 of the total award on each monthly anniversary of the Grant Date; provided, however, that notwithstanding the monthly vesting schedule, the options shall vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the next annual meeting of the stockholders."}],"balance_after":37500,"derivative":{"exercise_price":1.87,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-23-033667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000120919123033667/doc4.xml","form_type":"4"}},{"id":2017033,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-02-14T16:07:57.000Z","date":"2023-02-10","kind":"purchase","acquired":true,"shares":299401,"price":0.835,"value":249999.835,"ownership":{"direct":true},"balance_after":1635401,"source":{"system":"sec-edgar","filing":"0001104659-23-021607","document":"tm236803-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000110465923021607/tm236803-2_4seq1.xml","form_type":"4"}},{"id":2068789,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-01-04T21:25:28.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January 1, 2024, 2025 and 2026, subject to continued service."}],"balance_after":1336000,"source":{"system":"sec-edgar","filing":"0001104659-23-001097","document":"tm231728-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000110465923001097/tm231728-4_4seq1.xml","form_type":"4"}},{"id":2204072,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-21T16:16:52.000Z","date":"2022-07-19","kind":"other","acquired":true,"shares":1163861,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By JJL Pardes, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The reported transaction represents the acquisition by JJL Pardes, LLC of the securites listed in this row through a pro rata distribution made by GMF Pardes, LLC.  The reporting person is the sole managing member of JJL Pardes, LLC."}],"balance_after":1163861,"source":{"system":"sec-edgar","filing":"0001209191-22-042848","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000120919122042848/doc4.xml","form_type":"4"}},{"id":2204071,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-21T16:16:52.000Z","date":"2022-07-19","kind":"other","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transaction represents the acquisition by the reporting person of direct beneficial ownership of the securites listed in this row through a pro rata distribution made by GMF Pardes, LLC."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001209191-22-042848","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000120919122042848/doc4.xml","form_type":"4"}},{"id":2204070,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-21T16:16:52.000Z","date":"2022-07-19","kind":"other","acquired":false,"shares":3591265,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By GMF Pardes LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was a pro rata distribution made by GMF Pardes, LLC.  At the time of the distribution and as of the date hereof, the reporting person was one of 3 managing members of GMF Pardes, LLC.  The reporting person disclaims beneficial ownership of the shares reported in this row except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-042848","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000120919122042848/doc4.xml","form_type":"4"}},{"id":2236453,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T16:28:26.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continued service to the Issuer on each applicable vesting date, the option vests as to 1/12 of the total award on each monthly anniversary of the Grant Date; provided, however, that notwithstanding the monthly vesting schedule, the options shall vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the next annual meeting of the stockholders."}],"balance_after":37500,"derivative":{"exercise_price":5.21,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-22-035903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000120919122035903/doc4.xml","form_type":"4"}},{"id":2288036,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2022-04-29T16:18:14.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service."}],"balance_after":1236000,"source":{"system":"sec-edgar","filing":"0001104659-22-053578","document":"tm2213913-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000110465922053578/tm2213913-3_4seq1.xml","form_type":"4"}},{"id":2457996,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-28T16:30:33.000Z","date":"2021-12-23","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in substantially equal monthly installments over three years, subject to a continued service relationship. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2021 Stock Option and Incentive Plan with the U.S. Securities and Exchange Commission."}],"balance_after":75000,"derivative":{"exercise_price":9.8,"expiration_date":"2031-12-22","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-21-049932","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000089924321049932/doc4.xml","form_type":"4"}},{"id":2752220,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2021-04-09T17:23:17.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January 1, 2022, 2023 and 2024, subject to continued service."}],"balance_after":1136000,"source":{"system":"sec-edgar","filing":"0001104659-21-048827","document":"tm219139d4_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000110465921048827/tm219139d4_4.xml","form_type":"4"}},{"id":3211391,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2020-03-13T16:07:22.000Z","date":"2020-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January 1, 2021, 2022 and 2023, subject to continued service."}],"balance_after":1036000,"source":{"system":"sec-edgar","filing":"0001104659-20-033113","document":"tm2011481-4_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000110465920033113/tm2011481-4_form4.xml","form_type":"4"}},{"id":3556756,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-12T16:09:50.000Z","date":"2019-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January 1, 2020, 2021 and 2022, subject to continued service."}],"balance_after":936000,"source":{"system":"sec-edgar","filing":"0001144204-19-019497","document":"tv516219_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000114420419019497/tv516219_4.xml","form_type":"4"}},{"id":3747769,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-30T17:28:16.000Z","date":"2018-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January 1, 2019, 2020, and 2021, subject to continued service."}],"balance_after":786000,"source":{"system":"sec-edgar","filing":"0001144204-18-062678","document":"tv495940_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000114420418062678/tv495940_4.xml","form_type":"4"}},{"id":4483110,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2017-01-24T19:01:41.000Z","date":"2017-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January 1, 2018, 2019 and 2020, and subject to continued service on the board of directors."}],"balance_after":686000,"source":{"system":"sec-edgar","filing":"0001638599-17-000108","document":"doc4_4431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000163859917000108/doc4_4431.xml","form_type":"4"}}]}